Friday, June 15, 2012 5:18:48 PM
This is one of the most irrelevant and skewed articles I've ever read. Based on your previous work, as many have already mentioned, you are hardly the person who should be making comments on the future of OPKO Health.
I will give you this; you're pretty good at twisting facts and drawing illogical conclusions that perhaps your "followers" may believe. I have to hand it to you, you almost convinced me that Dr. Frost supports fraudulent Chinese companies; that is the way it sounded by the way you reported. The way you write, you'd think Dr. Frost is an investment God of some sort who has a horrible past of failing his "people." Dr. Frost is an individual, a very wealthy and successful one at that, who has made many extremely high-payout investments with his own money. He doesn't force anyone to follow his investments, unlike the way you make it sound in this article. However, he does maintain a large following because of his large portfolio of successful investments, evident in his astounding net worth, whether you like it or not.
I'm also wondering why you're even criticizing Dr. Frost in the first place. Why do you care where and how much he chooses to invest? You make it sound like a bad thing that Dr. Frost sticks with companies even when they aren't performing that well. Above anything else, it's a sign of loyalty as well as a strong stance of faith from the respected investor who will likely help the company he has a stake in to turn around. As noted by someone above, SafeStitch may have taken a turn for the worse, but since January it has been climbing back up; do you think it'd be continuing to climb if Dr. Frost ditched the company in a rough time? No. And all you can focus on is the companies failure to succeed.
It seems you really needed to do a lot of research to find poor investments he has made; Dr. Frost has made a lot more smarter decisions than failed investments. Regardless, the ones that have failed don't need to be criticized. Why does it matter if a risk, that was KNOWN to be a risk, ended up not working out? It's his money, and he chose to take that risk. You act like he is to blame for leading on investors who may be following his decisions.
You are a great writer when it comes to skewing facts and tricking the general public who don't have a basic knowledge of investing or Dr. Frost. Other than that, you're not much. As far as Protalix goes, Dr. Frost has actually made $70 million overall, but of course the only reference you could make was that he lost $300 million in a day. As for most other "losses," you seemed to only claim them in market valuation, failing to denote actual dollar loss, as mentioned above by gregsilver. As far as OPKO Health goes, you again only seem to notice the negatives. First of all, they are in a good position currently, and all you can talk about is the possibility of them failing. Sure, there's a possibility, but there's also a much better chance that they will succeed, especially with the help of Dr. Frost and his will to stick by them even when they're in the gutter. If he wanted to, Dr. Frost could buy back 2/3 of the float, or even the entire float of OPKO Health, which would most likely boost the stock to somewhere around $9.
Just for the sake of it, here's some more investments Dr. Frost has successfully made:
-Dreams
-ContinuedCare
-Whitman Education
-Key Pharmeceutical
-Ivax
-North American Vaccine
-Prolor
-ChromaDex
These probably don't count though, right?
I'd tell you to do your research next time you write an article, but it's clear that you have. Next time, though, spend more time researching both sides of the story instead of reporting a skewed article that does nothing but make you look like a bashful, immature, and uneducated writer.
Recent CDXC News
- ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC) • Business Wire • 06/13/2024 12:32:00 PM
- ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT) • Business Wire • 06/07/2024 12:34:00 PM
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024 • Business Wire • 06/04/2024 12:32:00 PM
- ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 • Business Wire • 05/23/2024 12:34:00 PM
- ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award • Business Wire • 05/22/2024 12:32:00 PM
- ChromaDex Corporation Reports First Quarter 2024 Financial Results • Business Wire • 05/08/2024 08:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:02:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:01:05 PM
- ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement • Business Wire • 04/30/2024 12:32:00 PM
- ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® • Business Wire • 04/25/2024 12:34:00 PM
- ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 • Business Wire • 04/24/2024 12:34:00 PM
- ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market • Business Wire • 04/23/2024 12:32:00 PM
- ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program • Business Wire • 03/26/2024 12:32:00 PM
- ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results • Business Wire • 03/06/2024 09:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:02:29 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:01:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 02:00:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 01:59:47 AM
- ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024 • Business Wire • 02/21/2024 01:32:00 PM
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024 • Business Wire • 02/05/2024 01:32:00 PM
- ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference • Business Wire • 01/26/2024 09:08:00 PM
- ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen® • Business Wire • 12/20/2023 02:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:00:16 PM
- Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+ • PR Newswire (US) • 12/12/2023 03:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/04/2023 09:12:33 PM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM